Rhythm Management

Left Atrial Appendage Isolation in Patients Not Responding to Pulmonary Vein Isolation – Benefit and Risks

Journal Articles: Pulmonary vein isolation (PVI) is an effective strategy for patients with paroxysmal atrial fibrillation (AF).1 However, in patients with persistent AF and long-standing persistent AF, PVI is associated with limited success, with patients not responding to PVI.2 Recently, the BELIEF trial (Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure Outcome in Patients With Persistent or Longstanding Persistent Atrial Fibrillation Undergoing Catheter Ablation) showed that an electric isolation of the left atrial (LA) appendage (LAA) in addition to PVI could increase clinical success.3 Although potentially effective, this strategy causes electromechanical dissociation of the LAA and was assumed to be associated with increased risk for LAA thrombus and thromboembolism.4 We sought to investigate the incidence of LAA thrombus and thromboembolism and the impact of LAA closure on the prevention of thromboembolic events, in addition to the clinical benefit after left atrial appendage isolation (LAAI).

ED AF <48h Protocol

Order Sets: ED AF <48h Protocol

ED AF >48h/Unknown Duration Protocol

Order Sets: ED AF >48h/Unknown Duration Protocol

Outpatient Management of Atrial Fibrillation

Care Pathways/CDS: Care pathway and decision support tool for use in the outpatient management of AFib patients. Includes when to consider early consultation, AV nodal blocking therapies, modifiable risk factors, and need for anti-coagulation.

Emergency Department Management of AF

Care Pathways/CDS: Care pathway and decision support tool for use in the emergency department when patient presents with ECG-confirmed AFib. Includes pathway exclusion criteria and link to full guideline.

ED-AFib Pathway

Care Pathways/CDS: A Multidisciplinary Approach to Managing Patients with AFib in the Emergency Department

Arrhythmias in Pregnancy

Journal Articles: Increasing maternal mortality and incidence of arrhythmias in pregnancy have been noted over the past 2 decades in the United States. Pregnancy is associated with a greater risk of arrhythmias, and patients with a history of arrhythmias are at significant risk of arrhythmia recurrence during pregnancy. The incidence of atrial fibrillation in pregnancy is rising. This review discusses the management of tachyarrhythmias and bradyarrhythmias in pregnancy, including management of cardiac arrest. Management of fetal arrhythmias are also reviewed. For patients without structural heart disease, bblocker therapy, especially propranolol and metoprolol, and antiarrhythmic drugs, such as flecainide and sotalol, can be safely used to treat tachyarrhythmias. As a last resort, catheter ablation with minimal fluoroscopy can be performed. Device implantation can be safely performed with minimal fluoroscopy and under echocardiographic or ultrasound guidance in patients with clear indications for devices during pregnancy. Because of rising maternal mortality in the United States, which is partly driven by increasing maternal age and comorbidities, a multidisciplinary and/or integrative approach to arrhythmia management from the prepartum to the postpartum period is needed. (J Am Coll Cardiol EP 2022;8:120–135) © 2022 by the American College of Cardiology Foundation.

SOP Atrial Fibrillation Therapy

Care Pathways/CDS: SOP for therapy options when treating AFib. Includes flow chart, decision trees, chart for AAD dosage, and risk factors/comorbidities.

Suspected Atrial Fibrillation

Care Pathways/CDS: Clinical pathway for suspected atrial fibrillation.

Confirmed AF Management Pathway

Care Pathways/CDS: Care pathway for management of confirmed AFib in patients. Includes information about underlying causes, treatment options, reducing stroke risk, and more.